Core Viewpoint - PureTech Health plc has appointed Robert Lyne as the new Chief Executive Officer (CEO), effective immediately, marking a significant leadership transition for the company [1][2]. Company Leadership - Robert Lyne expressed his honor in leading PureTech at a pivotal moment, emphasizing the strength of the company's programs and the talent of its team [2]. - The Board of Directors supports Lyne's appointment, highlighting his strong leadership and strategic clarity during his tenure as Interim CEO [4]. Strategic Focus - The immediate focus for the company is to secure funding for Celea Therapeutics, following a successful End-of-Phase 2 meeting with the U.S. FDA, with expectations to close funding within the first half of 2026 [3]. - PureTech plans to operate with a streamlined structure and reduced overhead, pursuing capital-efficient innovation initiatives to enhance shareholder returns [4]. Financial Strategy - Once Celea is fully financed, the company will evaluate methods to deliver value to shareholders, including potential capital returns, while maintaining a disciplined investment posture [4]. - The company aims to preserve capital and maintain flexibility to position itself for future value creation [4]. Company Background - PureTech Health is a biotherapeutics company focused on transforming innovation into value through a capital-efficient R&D model, having produced multiple therapeutic candidates, including three that received U.S. FDA approval [6].